Loading stock data…
$5.50-0.01 (-0.18%)
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases.
Aligos Therapeutics, Inc. in the Healthcare sector is trading at $5.50 with a market capitalization of $39M. Wall Street consensus targets $52.38 (8 analysts), implying a +852.3% move over the next 12 months. The stock is currently near its 52-week low of $3.98, remaining 15.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $27.78M↑ | $2.83M↑ | $169,000↓ | $741,000↓ | $965,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$1.89M↑ | -$26.93M↓ | -$21.81M↑ | -$28.36M↓ | -$18.57M |
| Net Income | -$1.50M↑ | -$23.04M↓ | -$19.88M↑ | -$31.54M↓ | -$15.86M |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is...